219 related articles for article (PubMed ID: 31581353)
1. Novel fatty acid-thiadiazole derivatives as potential antimycobacterial agents.
Mali JK; Sutar YB; Pahelkar AR; Verma PM; Telvekar VN
Chem Biol Drug Des; 2020 Jan; 95(1):174-181. PubMed ID: 31581353
[TBL] [Abstract][Full Text] [Related]
2. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
4. First triclosan-based macrocyclic inhibitors of InhA enzyme.
Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
[TBL] [Abstract][Full Text] [Related]
5. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
[TBL] [Abstract][Full Text] [Related]
6. Novel peptidomimetic peptide deformylase (PDF) inhibitors of Mycobacterium tuberculosis.
Gokhale KM; Telvekar VN
Chem Biol Drug Des; 2021 Jan; 97(1):148-156. PubMed ID: 32745362
[TBL] [Abstract][Full Text] [Related]
7. Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents.
Ramprasad J; Nayak N; Dalimba U
Eur J Med Chem; 2015 Dec; 106():75-84. PubMed ID: 26520841
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, evaluation and in silico molecular modeling of pyrroyl-1,3,4-thiadiazole inhibitors of InhA.
Joshi SD; More UA; Koli D; Kulkarni MS; Nadagouda MN; Aminabhavi TM
Bioorg Chem; 2015 Apr; 59():151-67. PubMed ID: 25800133
[TBL] [Abstract][Full Text] [Related]
9. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
Matviiuk T; Madacki J; Mori G; Orena BS; Menendez C; Kysil A; André-Barrès C; Rodriguez F; Korduláková J; Mallet-Ladeira S; Voitenko Z; Pasca MR; Lherbet C; Baltas M
Eur J Med Chem; 2016 Nov; 123():462-475. PubMed ID: 27490025
[TBL] [Abstract][Full Text] [Related]
10. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
[TBL] [Abstract][Full Text] [Related]
11. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
[TBL] [Abstract][Full Text] [Related]
12. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Saharan VD; Mahajan SS
Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.
Joshi SD; Dixit SR; Kirankumar MN; Aminabhavi TM; Raju KV; Narayan R; Lherbet C; Yang KS
Eur J Med Chem; 2016 Jan; 107():133-52. PubMed ID: 26580979
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
He X; Alian A; Ortiz de Montellano PR
Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents.
Menendez C; Gau S; Lherbet C; Rodriguez F; Inard C; Pasca MR; Baltas M
Eur J Med Chem; 2011 Nov; 46(11):5524-31. PubMed ID: 21944473
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity.
Pflégr V; Horváth L; Stolaříková J; Pál A; Korduláková J; Bősze S; Vinšová J; Krátký M
Eur J Med Chem; 2021 Nov; 223():113668. PubMed ID: 34198149
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
20. Antituberculosis agents. V. Synthesis, evaluation of in vitro antituberculosis activity and cytotoxicity of some 2-(5-nitro-2-furyl)-1,3,4-thiadiazole derivatives.
Foroumadi A; Asadipour A; Mirzaei M; Karimi J; Emami S
Farmaco; 2002 Sep; 57(9):765-9. PubMed ID: 12385528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
